drugset / Trial / NCT07145333
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Phase 2/3
Active not recruiting
600 enrolled
Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
UnitedHealthcare · collab
RandomizedParallel-groupQuadruple-blindHealth-services research
Summary
Explore the relationship between drug target topoisomerase I gene single nucleotide polymorphisms and Topotecan therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Topotecan side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Timeline
- Start
- 2026-10-05
- Primary completion
- 2026-12-18
- Completion
- 2027-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | — | — |